Startseite/Aktien/IXHL

IXHL

USD

Incannex Healthcare Inc. Common Stock

$0.339-0.005 (-1.480%)

Echtzeitkurs

Healthcare

Drug Manufacturers - Specialty & Generic

Australien

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen

Unternehmensfundamentaldaten

Handelsstatistiken

Marktkennzahlen

Eröffnung

$0.344

Hoch

$0.349

Tief

$0.336

Volumen

15.84M

Unternehmensfundamentaldaten

Marktkapitalisierung

118.0M

Branche

Drug Manufacturers - Specialty & Generic

Land

Australia

Handelsstatistiken

Durchschnittliches Volumen

66.44M

Börse

NCM

Währung

USD

52-Wochen-Spanne

Tief $0.08Aktuell $0.339Hoch $3.12

Ähnliche Nachrichten

26. Aug. 2025 · 12:00

GlobeNewswire

Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder

MELBOURNE, Australia and NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company") is pleased to report positive data from its Phase 2 clinical trial of PSX-001

Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder

22. Aug. 2025 · 12:00

GlobeNewswire

Incannex Healthcare Authorizes $20 Million Share Repurchase Program

MELBOURNE, Australia and NEW YORK, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company developing innovative combination

Incannex Healthcare Authorizes $20 Million Share Repurchase Program

8. Aug. 2025 · 12:00

GlobeNewswire

Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea

MELBOURNE, Australia and NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage pharmaceutical company developing innovative combination therapies for prevalent medical